Expertise in
5
conditions

Valerie Gounant

Paris, FR 
Expertise in
5
conditions
Paris, FR 

Overview

Valerie Gounant practices practicing medicine in Paris, France.

Ms. Gounant is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Endoscopy, and Lung Transplant.

She is actively involved in clinical research, co-authoring 119 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Paris, France
Other Locations
Clichy-sous-bois, 92110, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other
Study Phase: Not Applicable
Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy
Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Atezolizumab
Study Phase: Phase 3
A Phase II Single-arm Trial Evaluating Safety and Efficacy of Durvalumab in ECOG Performance Status 2-3, Treatment-naive, Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) and High PD-L1 Tumor Expression
A Phase II Single-arm Trial Evaluating Safety and Efficacy of Durvalumab in ECOG Performance Status 2-3, Treatment-naive, Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) and High PD-L1 Tumor Expression
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase II Non-randomized, Single Group Assignment, Open-label, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
A Phase II Non-randomized, Single Group Assignment, Open-label, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 01, 2025
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial
Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial
Enrollment Status: Completed
Publish Date: May 12, 2023
Intervention Type: Drug
Study Drug: Nivolumab Injection
Study Phase: Phase 2
Phase II Study Evaluating the Combination of Cetuximab With Afatinib as First-line Treatment for Patients With EGFR Mutated Non Small Cell Lung Cancer
Phase II Study Evaluating the Combination of Cetuximab With Afatinib as First-line Treatment for Patients With EGFR Mutated Non Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 11, 2022
Intervention Type: Drug
Study Drugs: Afatinib, Cetuximab
Study Phase: Phase 2
View 6 Less Clinical Trials

119 Total Publications

Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE.
Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE.
Journal: Respiratory medicine and research
Published: May 19, 2026

Frequently Asked Questions about Valerie Gounant

Is Valerie Gounant a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Valerie Gounant is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Valerie Gounant participate in research or clinical trials?

Yes. Valerie Gounant has published 119 articles and abstracts on conditions like Lung Cancer. You can view a list of Valerie Gounant's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gounant's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile